Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis
Open Access
- 17 May 2016
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0153380
Abstract
We aimed to compare the safety of antidepressants for the treatment of persistent depressive disorder (PDD) with each other and with placebo. We conducted a systematic electronic search and included randomized controlled trials that investigated antidepressants for the treatment of PDD in adults. Outcomes were the incidence of experiencing any adverse event, specific adverse events and related treatment discontinuations. We analyzed the data using traditional and network meta-analyses. Thirty-four studies that comprised 4,769 patients and examined 20 individual agents in nine substance classes were included. Almost all analyzed substance classes were associated with higher discontinuation rates than placebo including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), antipsychotics, and the serotonin antagonist and reuptake inhibitor (SARI) trazodone. The odds of experiencing any adverse event were significantly higher for TCAs and serotonin noradrenaline reuptake inhibitors (SNRIs) compared to placebo. Pairwise comparisons among the substance classes revealed that more patients receiving TCAs or SNRIs experienced any adverse event and that more patients receiving TCAs or the SARI trazodone discontinued treatment. The complementary treatment with acetyl-l-carnitine showed lower rates of experiencing any adverse event and related discontinuations than all other comparators. TCAs were primarily associated with (anti-)cholinergic and sedating adverse events. SSRIs primarily showed gastrointestinal adverse events. Patients treated with the antipsychotic amisulpride were more likely to manifest weight gain and endocrine adverse events. The comparative evidence for further agents was insufficient or lacking. The identified safety differences may be used to inform the selection among the antidepressants.Keywords
Funding Information
- University Medical Center Hamburg-Eppendorf (NWF-14/06)
This publication has 42 references indexed in Scilit:
- A graphical tool for locating inconsistency in network meta-analysesBMC Medical Research Methodology, 2013
- Lessons learned from placebo groups in antidepressant trialsPhilosophical Transactions of the Royal Society B: Biological Sciences, 2011
- Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic ApproachPLOS ONE, 2011
- Effectiveness of psychotherapeutic, pharmacological, and combined treatments for chronic depression: a systematic review (METACHRON)BMC Psychiatry, 2010
- Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicinesArthritis Care & Research, 2010
- Chronic DepressionCurrent Directions in Psychological Science, 2010
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Severe Adverse Drug Reactions of Antidepressants: Results of the German Multicenter Drug Surveillance Program AMSPPharmacopsychiatry, 2004
- Pharmacotherapy for dysthymiaCochrane Database of Systematic Reviews, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986